Phase Ia multi-center, blinded, placebo-controlled, single-ascending dose study of VRS-859 in patients with type 2 diabetes mellitus
Phase of Trial: Phase I
Latest Information Update: 08 Jun 2016
At a glance
- Drugs Exenatide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- 08 Jan 2016 In Dec 2015, company announced positive results from this trial, as per Flamel media release.
- 05 Oct 2012 Results presented at the 48th Annual Meeting of the European Association for the Study of Diabetes.
- 05 Oct 2012 EudraCT2010-019182-29 added as identifier, as reported in the abstract presented at EASD.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History